Further, by using this same adjuvant (a TLR-9 agonist), Muraoka et al.[44] modified a defective CD8+ T cell-mediated anti-tumor immune response to a productive one by counteracting the aberrant expression of CD95 and PD1 on CD8+ T cells. Here, FAS is linked to neoplasm.